Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Dilazep. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A known ✓ | P35498 | 2/20 | 0.95 |
| ▸ | SCN2A known ✓ | Q99250 | 2/20 | 0.95 |
| ▸ | SCN3A known ✓ | Q9NY46 | 2/20 | 0.95 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.95 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.95 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.95 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.95 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.95 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.95 |
| ▸ | GHSR known ✓ | Q92847 | 1/20 | 0.95 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.95 |
| ▸ | HTR4 known ✓ | Q13639 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.98 |
| ▸ | MEN1 | O00255 | 4/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.98 |
| ▸ | LMNA | P02545 | 2/20 | 0.98 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.98 |
| ▸ | GMNN | O75496 | 1/20 | 0.98 |
| ▸ | BLM | P54132 | 1/20 | 0.98 |
| ▸ | SLC29A1 | Q99808 | 10/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dilazep SCHEMBL220842 | 0.99 | SMN1; SMN2 (1.00) | SMN1; SMN2MEN1KMT2ALMNAPMP22 | |
| Dilazep SCHEMBL349239 | 0.99 | SMN1; SMN2 (1.00) | SMN1; SMN2MEN1KMT2ALMNAPMP22 | |
| Dilazep SCHEMBL2597896 | 0.97 | SLC29A1 (1.00) | SMN1; SMN2MEN1KMT2ALMNAPMP22 | |
| Dilazep SCHEMBL48830 | 0.97 | SLC29A1 (1.00) | SMN1; SMN2MEN1KMT2ALMNAPMP22 | |
| Dilazep SCHEMBL15532226 | 0.95 | SLC29A1 (0.95) | SMN1; SMN2MEN1KMT2ALMNAPMP22 | |
| SCHEMBL27319577 | 0.91 | SLC29A1 (0.87) | SMN1; SMN2MEN1KMT2ALMNAPMP22 | |
| SCHEMBL2459734 | 0.89 | SLC29A1 (0.83) | SMN1; SMN2MEN1KMT2ALMNAPMP22 | |
| SCHEMBL27319054 | 0.89 | SLC29A1 (0.83) | SMN1; SMN2MEN1KMT2ALMNAPMP22 | |
| SCHEMBL8686213 | 0.86 | SLC29A1 (0.79) | SMN1; SMN2MEN1KMT2ALMNAPMP22 | |
| Dilazep SCHEMBL11130839 | 0.85 | SLC29A1 (0.77) | SMN1; SMN2MEN1KMT2ALMNAPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4393512-A1 | COMPOSITION FOR MEDICINAL TABLET, MEDICINAL TABLET OBTAINED USING SAME, AND PRODUCTION METHOD THEREFOR | Mitsubishi Chemical Corporation (JP) | 2024-07-03 | — | — | EP | disclosed |
| US-20240173260-A1 | COMPOSITION FOR PHARMACEUTICAL TABLET, PHARMACEUTICAL TABLET USING THE SAME, AND MANUFACTURING METHOD THEREOF | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-05-30 | — | — | US | disclosed |
| EP-4316469-A1 | COMPOSITION FOR SUSTAINED-RELEASE SOLID PREPARATION, SUSTAINED-RELEASE TABLET USING SAME AND MANUFACTURE METHOD THEREOF | Mitsubishi Chemical Corporation (JP) | 2024-02-07 | — | — | EP | disclosed |
| US-20240016745-A1 | TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | TOWA PHARMACEUTICAL CO., LTD. (JP) | 2024-01-18 | — | — | US | disclosed |
| US-20240000712-A1 | COMPOSITION FOR SUSTAINED-RELEASE SOLID DOSAGE FORM, SUSTAINED-RELEASE TABLET USING THE SAME, AND MANUFACTURING METHOD THEREOF | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-01-04 | — | — | US | disclosed |
| EP-4260847-A1 | TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING SAME | TOWA PHARMACEUTICAL CO., LTD. (JP) | 2023-10-18 | — | — | EP | disclosed |
| WO-2023155886-A1 | PYRAZOLOPYRIDINE COMPOUNDS AS TAM INHIBITORS | SHANGHAI ANTENGENE CORPORATION LIMITED (CN) | 2023-08-24 | — | — | WO | disclosed |
| US-20230158076-A1 | AGENT FOR INCREASING CD25-POSITIVE REGULATORY T CELLS IN KIDNEYS | NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (JP) | 2023-05-25 | — | — | US | disclosed |
| WO-2023051464-A1 | PYRAZOLOPYRIDINE COMPOUNDS AS TAM INHIBITORS | SHANGHAI ANTENGENE CORPORATION LIMITED (CN) | 2023-04-06 | — | — | WO | disclosed |
| EP-4137141-A1 | AGENT FOR INCREASING CD25-POSITIVE REGULATORY T CELLS IN KIDNEY | National University Corporation Tokai National Higher Education and Research System (JP) | 2023-02-22 | — | — | EP | disclosed |
| US-20160264579-A1 | PYRROLO PYRIMIDINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-09-15 | — | — | US | disclosed |
| EP-3067356-A1 | PYRROLO PYRIMIDINE DERIVATIVE | ONO Pharmaceutical Co., Ltd. (JP) | 2016-09-14 | — | — | EP | disclosed |
| US-20160168121-A1 | QUINOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-06-16 | — | — | US | disclosed |
| EP-3023109-A1 | ORALLY DISINTEGRATING TABLET | Sanwa Kagaku Kenkyusho Co., Ltd (JP) | 2016-05-25 | — | — | EP | disclosed |
| US-20160136091-A1 | Orally Disintegrating Tablet | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2016-05-19 | — | — | US | disclosed |
| US-8900602-B2 | Disintegrating particle composition and orally rapidly disintegrating tablet | FUJI CHEMICAL INDUSTRY CO., LTD. (JP) | 2014-12-02 | — | — | US | disclosed |
| US-20120165413-A1 | DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET | FUJI CHEMICAL INDUSTRY CO., LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
| US-20120156261-A1 | DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET | FUJI CHEMICAL INDUSTRY CO., LTD. (JP) | 2012-06-21 | — | — | US | disclosed |
| EP-2465539-A1 | DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET | FUJI CHEMICAL INDUSTRY CO., LTD. (JP) | 2012-06-20 | — | — | EP | disclosed |
| EP-2465540-A1 | DISINTEGRATING PARTICLE COMPOSITION AND ORALLY RAPIDLY DISINTEGRATING TABLET | FUJI CHEMICAL INDUSTRY CO., LTD. (JP) | 2012-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264579-A1 | PYRROLO PYRIMIDINE DERIVATIVE | AXL, FLT3, TYRO3 | SCN1A 4742/4885SCN2A 4812/4885SCN3A 4833/4885 |
| US-20160168121-A1 | QUINOLINE DERIVATIVE | FLT3, AXL, ERBB2 | SCN1A 4028/4885SCN2A 3958/4885SCN3A 4279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.